Results 171 to 180 of about 41,275 (293)

Hippo Pathway–YAP/TAZ Signaling: Molecular Mechanisms, Biological Function, Diseases, and Therapeutic Targets

MedComm, Volume 7, Issue 10, October 2026.
The Hippo–YAP/TAZ–TEAD pathway integrates mechanical and biochemical cues to govern organ growth, regeneration, cancer, and fibrosis. This review dissects pathway physiology, TEAD structural pharmacology and ligandable pockets, and therapeutic strategies spanning palmitoylation‐pocket inhibitors, PROTAC degraders, and gene/RNA therapies, highlighting ...
Xiaodan Qu, Zhan‐you Wang
wiley   +1 more source

Virtual Screening-Guided Identification of Candidate USP7-Inhibitory Scaffolds Exhibiting Antiproliferative Activity. [PDF]

Pharmaceuticals (Basel)
Oliveira RI, Franco C, Mano M, Leal AS, Salvador JAR.   +4 more
europepmc   +1 more source

Naltrexone, Naloxone, Morphine, and Fentanyl Pharmacologically Chaperone a Mutant μ‐Opioid Receptor via an Endoplasmic Reticulum Exit Site‐Dependent Pathway

Pharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.
ABSTRACT Opioid receptor antagonists increase the plasma membrane density of μ‐opioid receptors (MOR) in vivo, thereby inducing “supersensitivity” to opioid agonists. This phenomenon increases the risk of overdose in patients that were being treated with naltrexone (Ntx), a popular MOR antagonist.
Stephen N. Grant, Matthew J. Mulcahy, Henry A. Lester   +2 more
wiley   +1 more source

Correction: Pharmacophore modeling, docking and the integrated use of a ligand- and structure-based virtual screening approach for novel DNA gyrase inhibitors: synthetic and biological evaluation studies. [PDF]

RSC Adv
Mathpal D, Masand M, Thomas A, Ahmad I, Saeed M, Zaman GS, Kamal M, Jawaid T, Sharma PK, Gupta MM, Kumar S, Srivastava SP, Balaramnavar VM.   +12 more
europepmc   +1 more source

Dualsteric and dual‐acting modulation of muscarinic receptors by antagonist KH‐5

British Journal of Pharmacology, Volume 183, Issue 19, Page 5769-5790, October 2026.
Abstract Background and purpose Muscarinic acetylcholine receptors are key therapeutic targets, and ligands engaging both orthosteric and allosteric sites may offer improved selectivity and efficacy. Here, we investigated whether the muscarinic antagonist KH‐5 acts as a dualsteric antagonist and defined its mode of interaction with muscarinic receptors.
Alena Janoušková‐Randáková, Eva Dolejší, Nikolai Chetverikov, Jan Jakubík   +3 more
wiley   +1 more source

Discovery of a Reversible Sub‐Picomolar Thrombin Inhibitor Using DCC

Angewandte Chemie, Volume 138, Issue 38, 14 September 2026.
An ultrapotent yet fully reversible trivalent thrombin inhibitor discovered through screening a large dynamic combinatorial library (DCL) of 125 000 members of self‐assembled fragments. The innovative approach leverages size‐exclusion‐based affinity selection, coupled with MALDI‐TOF mass spectrometry readout, enabling the full workflow to be completed ...
Millicent Dockerill, Richard J. Payne, Nicolas Winssinger   +2 more
wiley   +2 more sources

PharmaGNN: a model for odor prediction based on graph neural networks. [PDF]

J Sci Food Agric
Liu Y, Song Q, Shoaib M, Nan X, Ma J, Cui K, Shang Y, Song J.   +7 more
europepmc   +1 more source

De Novo Discovery of Bioactive Cyclic Peptides via Cellular Selection of Genetically Encoded Libraries

ChemBioChem, Volume 27, Issue 18, 28 September 2026.
Genetically encoded cyclic peptide libraries can be employed in cellular selection platforms to identify cyclic peptide inhibitors for therapeutic targets by directly selecting for desired biological activities. This review systematically summarizes representative studies and suggests future opportunities for using cellular selection for de novo cyclic
Linwei Yang, Abhijit Behera, Hannah J. Meyers, Tina Wang   +3 more
wiley   +1 more source

Influence of N-Functionalization of Amiridine on the Biological Activity of Its Conjugates as Multitarget Agents for Potential Treatment of Alzheimer's Disease. [PDF]

ChemMedChem
Makhaeva GF, Astakhova TY, Grishchenko MV, Shteinberg TS, Kovaleva NV, Boltneva NP, Rudakova EV, Pronkin PG, Timokhina EN, Radchenko EV, Shchegolkov EV, Burgart YV, Saloutin VI, Charushin VN, Richardson RJ.   +14 more
europepmc   +1 more source

De Novo Molecular Design and Bioactivity Prediction of Novel Hexahydroquinolines as <i>Plasmodium falciparum</i> Calcium-Dependent Protein Kinase 4 (CDPK4) Inhibitors. [PDF]

Bioinform Biol Insights
Oduselu GO, Bodun DS, Ajani OO, Conway DJ, Amenga-Etego LN, Oyibo W, Awandare GA.   +6 more
europepmc   +1 more source